AGT and Hypokalemia: If the the angiotensin-II/aldosterone-dependent mechanism—causing massive renal potassium loss—is operative in human pathology, this implies that severe hypokalemia by SARS-CoV-2 infection may be amenable to treatment with potassium-sparing drugs antagonizing the aldosterone receptor, such as spironolactone or eplerenone, whereas potassium supplementation (whether oral or IV) even in very high doses may be futile.